Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-12
2009-12-29
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000, C424S422000
Reexamination Certificate
active
07638486
ABSTRACT:
Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension of the retention time of the intracellular enzymes and signaling molecules that play important roles to proliferate, differentiate, maturate, and/or mineralize the hard tissue forming cells.
REFERENCES:
patent: 5015628 (1991-05-01), Reynolds
patent: 5407644 (1995-04-01), Rytter et al.
patent: 5837674 (1998-11-01), Kumagai et al.
patent: 5846931 (1998-12-01), Hattersley et al.
patent: 5849865 (1998-12-01), Cheng et al.
patent: 6027592 (2000-02-01), Tseng et al.
patent: 6045780 (2000-04-01), Bixler et al.
patent: 6145655 (2000-11-01), Ruben
patent: 6300062 (2001-10-01), Cerny et al.
patent: 6329357 (2001-12-01), Norman et al.
patent: 6673900 (2004-01-01), Rowe
patent: 6790639 (2004-09-01), Brown et al.
patent: 6911425 (2005-06-01), Kumagai et al.
patent: 7271151 (2007-09-01), Rowe
patent: 2002/0102641 (2002-08-01), Schia Vi et al.
patent: 2002/0197267 (2002-12-01), Kumagai et al.
patent: 2003/0166239 (2003-09-01), Brown et al.
patent: 2004/0126375 (2004-07-01), Langenfeld
patent: 2004/0230310 (2004-11-01), Ferree
patent: 1 820 522 (2007-08-01), None
patent: 4-74132 (1992-03-01), None
patent: 4-506511 (1992-11-01), None
patent: 11-506672 (1999-06-01), None
patent: 11-318498 (1999-11-01), None
patent: 2002-500898 (2002-01-01), None
patent: 2002-512018 (2002-04-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 99/08730 (1999-02-01), None
patent: WO 99/48909 (1999-02-01), None
patent: WO 99/43844 (1999-09-01), None
patent: WO 99/48909 (1999-09-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 00/52041 (2000-09-01), None
patent: WO 01/72826 (2001-10-01), None
patent: WO 02/05836 (2002-01-01), None
patent: WO03/027246 (2003-04-01), None
patent: WO 03/066666 (2003-08-01), None
patent: WO 2006/078464 (2006-07-01), None
Abe et al., “Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamine D3”PNAS, 78(8):4990-4994 (1981).
Bairoch et al. (1990) “EF-hand motifs in inositol phospholipid-specific phospholipase C.”FEBS, vol. 269(2):454-456.
Bikle, “Vitamin D: New Actions, New Analogs, New Therapeutic Potential; Update 1995”Endocrine Review, 4(1):77-83 (1995).
Brenza et al., “Parathyroid hormone activation of the 25-hydroxyvitamine D3-1α-Hydroxylase gene promoter”PNAS95:1387-1391 (1998).
Carpenter, “New Perspectives on the Biology and Treatment of X-Linked Hypophsphatemic Rickets”Pediatric Endocrinology44(2):443-465 (1997).
Carswell, “The Potential for Treating Neurodegenerative Disorders with NGF-Inducing Compounds”Experimental Neurology, 124:36-42 (1993).
Chappard et al., (1995) “Effects of tiludronate on bone loss in paraplegic patients.”Journal of Bone and Mineral Research, 10(1):112-118.
Chauvaux et al. (1990) “Calcium-binding affinity and calcium-enhanced activity of Clostridium thermocellum endoglucanase D.”Biochem. J., vol. 265:261-265.
Davis (1990) “The many Faces of Epidermal Growth Factor Repeats.”The New Biologist, vol. 2(5):410-419.
Ecarot et al., “Defective Bone Formation by Hyp Mouse Bone Cells Transplanted into Normal Mice: Evidence in Favor of an Intrinsic Osteoblast Defect”Journal of Bone and Mineral Research, 7:215-200 (1992).
Ecarot et al., “Effect of 1,25-Dihydroxyvitamin D3 Treatment on Bone Formation by Transplanted Cells from Normal and X-Linked Hypophosphatemic Mice”Journal of Bone and Mineral Research, 10:424-431 (1995).
Economou et al. (1990) “The Rhizobium nodulation gene nodO encodes a Ca2+-binding protein that is exported without N-terminal cleavage and is homologous to haemolysin and related proteins.”The EMBO Journal, vol. 9(2):349-354.
Eto et al., “Assay of 25-Hydroxyvitamin D3 1 α-Hydroxylase in Rat Kidney Mitochondria”Analytical Biochemistry, 258:53-58 (1998).
Ferris D. M. et al., “RGD-coated titanium implants stimulate increased bone formation in vivo” Biomaterials, Vo. 20, No. 23-24, Dec. 1999. pp. 2323-2331.
Fisher et al., “Inhibition of Osteoclastic Bone Resorption in Vivo by Eschistatin an “Arginyol-Glycyl-Aspartyl” (RGD)-Containing Protein”Endocrinology, 132(3):1411-1413 (1993).
Fratzl et al., (1994) “Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study.”Journal of Bone and Mineral Research, 9(10):1541-1549.
Gennari et al., (1994) “Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.”Drug. Saf., 11(3):179-95.
George et al., “Characterization of a Novel Dentin Matrix Acidic Phosphoprotein”The Journal of Biological Chemistry, 268 (17):12624-12630 (1993).
Gronowicz et al., (1994) “Synthetic peptide containing Arg-Gly-Asp inhibits bone formation and resorption in a mineralizing organ culture system of fetal rat parietal bones.”Journal of Bone and Mineral Research, 9(2):193-201.
Hayashibara T. et al., “A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo” Journal of Bone and Mineral Research, New York, NY., US, vol. 19, No. 3, Mar. 2004, pp. 455-462.
Hewison et al., “1α-Hydroxylase and the action of vitamin D”Journal of Molecular Endocrinology, 25:141-148 (2000).
Hilfiker, (1998) “Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine.”Proc. Natl. Acad. Sci. USA, 95(24):14564-14569.
Horton et al., “Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23C6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts”Experimental Cell Research, 195:368-375 (1991).
Inomata et al., “Effect of 1α(OH)-vitamin D3 on insulin secretion in diabetes mellitus”Bone and Mineral, 1:187-192 (1986).
Kato et al., “Molecular Genetics of Vitamin D-Dependent Hereditary Rickets”Hormone Research, 57:73-78 (2002).
Kawasaki et al. (1995) “Calcium-Binding Proteins 1: EF-hands.”Protein Profile, vol. 2(4):305-356.
Kimmel-Jehan et al., “Cloning of the mouse 25-hydroxyvitamin D3-1α-hydroxylase (CYP1α) gene”Biochimica et Biophysica Acta, 1475:109-113 (2000).
Lajeunesse et al., “Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse”Kidney International50:1531-1538 (1996).
Lopez-Moratalla et al., “A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells” Biochimica et Biophysica Acta, vol. 1317, No. 3, 1996, pp. 183-191.
Lufkin et al., (1994) “Pamidronate: an unrecognized problem in gastrointestinal tolerability.”Osteoporos. Int., 4(6):320-322.
Martin et al., “Strategies to Minimize Bone Disease in Renal Failure”American Journal of Kidney Diseases, 38(6):1430-1436 (2001).
Meyer et al., “The Renal Phosphate Transport Defect in Normal Mice Parabiosed to X-Linked Hypophosphatemic Mice Persists After Parathyroidectomy”Journal of Bone and Mineral Research, 4(4):523-532 (1989).
Meyer et al., “Parabiosis Suggests a Humoral Factor Is Involved in X-Linked Hypophsphatemia in Mice”Journal of Bone and Mineral Research, 4(4):493-500 (1989).
Miller et al., “Genetics of vitamin D biosynthesis and its disorders”Best Practice&Research Clinical Endocrinology and Metabolism, 15(1):95-109 (2001).
Moncrief et al. (1990) “Evolution of EF-Hand Calcium-Modulated Proteins. I. Relationships Based on Amino Aci
Lazarov Mirella
Middleton-Hardie Catherine
Rosen David
Acologix, Inc.
Allen Marianne P
Bozicevic Karl
Bozicevic Field & Francis LLP
DeBerry Regina M
LandOfFree
Method for promoting hard tissue formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for promoting hard tissue formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for promoting hard tissue formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072673